期刊
JOURNAL OF PHARMACEUTICAL ANALYSIS
卷 11, 期 6, 页码 683-690出版社
ELSEVIER
DOI: 10.1016/j.jpha.2021.09.001
关键词
Drug repurposing; COVID-19; SARS-CoV-2; Virtual screening; 3C-like protease
资金
- Guangdong Medical University [B2019016]
- Adminis-tration of Traditional Chinese Medicine of Guangdong Province [20201180]
- Science and Technology Special Project of Zhanjiang [2019A01009]
- Natural Science Foundation of Guangdong Province [2016B030309002]
- Basic and Applied Basic Research Program of Guangdong Province [2019A1515110201]
- Educational Commission of Guangdong Prov-ince [4SG20138G]
- Fund of Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang) [ZJW-2019-007]
This article summarizes the current status of drug repurposing in COVID-19, which includes virtual computer screening, network pharmacology, and bioactivity-based drug repurposing, as a potentially beneficial treatment option for COVID-19.
Since December 2019, severe acute respiratory syndrome coronavirus 2 has been found to be the culprit in the coronavirus disease 2019 (COVID-19), causing a global pandemic. Despite the existence of many vaccine programs, the number of confirmed cases and fatalities due to COVID-19 is still increasing. Furthermore, a number of variants have been reported. Because of the absence of approved anticoronavirus drugs, the treatment and management of COVID-19 has become a global challenge. Under these circumstances, drug repurposing is an effective method to identify candidate drugs with a shorter cycle of clinical trials. Here, we summarize the current status of the application of drug repurposing in COVID-19, including drug repurposing based on virtual computer screening, network pharmacology, and bioactivity, which may be a beneficial COVID-19 treatment. (c) 2021 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据